Serum ARGS-aggrecan in a phase 2 clinical trial targeting osteoarthritis
Authors' conclusion
Systemic inhibition of ADAMTS-5 resulted in markedly reduced serum ARGS, but change in serum ARGS concentrations showed no association with the progression of cartilage thinning, or patient reported pain and function.
Study context
- Population
- ROCCELLA phase 2 trial participants with knee OA treated with ADAMTS-5 inhibition
- Comparison
- Once-daily oral S201086 75, 150 or 300 mg vs placebo for 52 weeks
Methodological detailsbiomarker analysis, linear regression
- Biomarker analysis
- Linear regression
Primary result
As reported in the abstract
Serum ARGS-aggrecan concentration
Maximal reduction of ARGS vs baseline, S201086 300 mg, at 4 weeks
58.5%
95% CI 60.8%, 56.2%
Further findings
Association of cumulative change in ARGS (baseline to week 52) with change in cartilage thickness (MRI) and WOMAC pain and function
- Cartilage thickness, slope
- −0.8×10-6 [−2.9×10-6, 1.3×10-6]
- WOMAC pain, slope
- −30×10-6 [−64×10-6, 5.2×10-6]
- WOMAC function, slope
- −97×10-6 [−214×10-6, 20×10-6]
- No effect
Original publication
Serum ARGS-aggrecan in a phase 2 clinical trial targeting osteoarthritis. Osteoarthritis Cartilage. Published 9 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →